Current research advance on cellular immunotherapy for leukemia-review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1326-1330, 2013.
Artículo
en Chino
| WPRIM
| ID: wpr-265020
ABSTRACT
Despite the chemotherapy is successful in inducing remission of hematologic malignancy, this disease also has a high probability of relapse; besides, the toxicity of chemotherapy for these patients can not be avoided. Researchers have been attempting to eliminate tumor cells by immunotherapy. Recently, various leukemia-associated antigens (LAA) that are recognized by cytotoxic T cell (CTL) in the context of HLA class I molecules have been identified. These LAA include WT1, PR-3, RHAMM, BCR-ABL and Aur-A. On the basis of these findings, various clinical trials of immunotherapy for hematologic malignancy including tumor peptide vaccination, adoptive T cell therapy, NK cell therapy and dendritic cells-cytokine induced killer (DC-CIK) cell therapy are on going. In this review, the current status and future feasibility of cellular immunotherapy for leukemia are discussed.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Terapéutica
/
Linfocitos T Citotóxicos
/
Leucemia
/
Inmunoterapia Adoptiva
/
Alergia e Inmunología
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2013
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS